POLISCOPE
Back to feed
HR6992FEDERALin_committee
High Impact

The MAPS Act: Mapping America’s Pharmaceutical Supply

Original title: MAPS Act

January 9, 2026

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action
Referred to the Subcommittee on Health.Jan 19, 2024
Lead sponsor

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

This bill mandates that the federal government track the production locations and volumes of critical drugs, which could lead to new regulatory oversight of pharmaceutical manufacturers and changes in how the U.S. manages drug supply security.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical Manufacturers

Companies must provide data on production locations, volumes, and regulatory history for inclusion in the federal supply chain database.

Department of Health and Human Services

The agency is tasked with establishing the essential medicines list, building the database, and reporting annually to Congress.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

The MAPS Act requires the Department of Health and Human Services (HHS) to create an official list of essential medicines and build a private database to track the U.S. pharmaceutical supply chain. This initiative aims to identify vulnerabilities in drug production and distribution to prevent shortages and address national security threats.

Key Facts

  • The Secretary of HHS must establish and maintain an official list of essential medicines and active pharmaceutical ingredients.
  • Essential medicines are defined as those needed for public health emergencies or those whose shortage would threaten the U.S. healthcare system.
  • The Secretary must publish a proposed initial list within 6 months of enactment and a final list within 1 year.
  • HHS must create a non-public database mapping the entire U.S. pharmaceutical supply chain, including production locations and volumes.
  • The database will track regulatory actions, including inspections, seizures, recalls, and drug shortages for listed items.
  • HHS must submit an annual report to Congress starting 18 months after enactment regarding supply chain visibility and industry cooperation.
  • The bill authorizes public-private partnerships to assist in mapping the supply chain.
  • Information in the database is protected from public disclosure, though HHS must still provide information to Congress.
  • The Secretary's compliance with this Act satisfies requirements under Executive Order 13944.

Frequently Asked Questions

Will the public be able to see the new pharmaceutical supply chain database?
No, the bill explicitly states that the information in the database shall not be publicly disclosed.
What criteria will be used to decide which drugs are 'essential'?
Drugs will be included if they are needed for public health emergencies, chemical/biological threats, or if a shortage would significantly threaten the U.S. healthcare system.
How often will the list of essential medicines be updated?
The Secretary of HHS is required to regularly review the list to determine if updates are necessary.

Why It Matters

This bill mandates that the federal government track the production locations and volumes of critical drugs, which could lead to new regulatory oversight of pharmaceutical manufacturers and changes in how the U.S. manages drug supply security.

News Coverage

Lobbying Activity

AARP

$4,110,000

2026

HEALTH ISSUESMEDICARE/MEDICAIDLAW ENFORCEMENT/CRIME/CRIMINAL JUSTICEPHARMACY

P.L. 119-21, One Big Beautiful Bill Act H.R. 8867, Planning for Long-term Aging Needs (PLAN) Act H.R. 5861, Legacy Act of 2025 H.R. 9393, the Lower Costs, More Transparency Act. H.R. 9396, the Prior Authorization Accountability Act. S. 4916, the Aging with Artificial Intelligence Act. H.R. 8100, Safe Staffing Saves Lives Act. S. 3886, Nurses Belong in Nursing Homes Act. H.R. 6766/S. 3492, the Essential Caregivers Act of 2025. H.R. 7966/S. 4118, Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act. S. 2120, the Older Americans Act Reauthorization Act of 2025 H.R. 5575, the Firefighters Assisting Seniors to Emergency Response (FASTER) Act of 2025. H.R. 3954/S. 4641, Improving Access to Medicare Coverage Act. H.R.5554/S.2831, Stand Strong for Medicare Act. S. 3439/H.R. 6735, Connecting Caregivers to Medicare Act and efforts related to the bill S. 1227/H.R. 2491, Alleviating Barriers for Caregivers Act S. 668/H.R. 3183, Supporting Access to Falls Education and Prevention and Strengthening Training Efforts and Promoting Safety Initiatives (SAFE STEPS) for Veterans Act of 2025 CMS-1851-P, Hospice Proposed rule. CMS-1843-P, Skilled Nursing Facility Proposed rule. CMS-1844-P, Home Health Proposed rule. No bill number. Health care transparency. No bill number. Discussed use of artificial intelligence and health data technology. No bill number. Discussed health-related policies and activities around the fall respiratory virus season. No bill number. Discussed health insurance affordability proposals. No bill number. Discussed Nursing Home staffing standards, safety, and quality. No bill number. Discussed Nursing home transparency and ownership requirements. No bill number. Discussed home health, hospice, and long-term care. No bill number. Discussed falls prevention. No bill number. Discussed social isolation. No bill number. Discussed HUD Assisted Living Requirements No bill number. Discussed family caregiving. No bill number. Discussed AARP paper on Medicare Caregiver Training Services. No bill number. Discussed Medicaid community engagement interim final rule, including the family caregiver exemption. No bill number. Discussed the paid direct care workforce in long-term care. No bill number. Discussed the unaffordability of long-term care. No bill number. Discussed Money Follows the Person Rebalancing Demonstration Program and Medicaid HCBS spousal impoverishment protections. No bill number. Discussed Medicaid fraud and family caregivers, Medicaid self-direction programs. No bill number. Discussed sandwich generation family caregiver hearing and submitted a statement for the record discussing family caregivers and sandwich generation caregivers, programs that support them, AARP caregiving resources, and federal policies to support sandwich generation caregivers and caregivers more broadly. No bill number. Discussed long-term care. No bill number. CMS-2453-NC; Medicaid Program; 2028 Medicaid Home and Community-Based Services Quality Measure Set Submitted comments No bill number. Discussed expanding access to home care. No bill number. Discussed the increasing cost of home care No bill number. Discussed HSA use for telehealth chronic care management services/subscriptions. No bill number. Discussed artificial intelligence and technology

LEWIS-BURKE ASSOCIATES, LLC

on behalf of UNIVERSITY OF ILLINOIS

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Increased Federal Oversight

The bill shifts from voluntary reporting to a mandated, comprehensive database of pharmaceutical production, signaling a move toward greater federal visibility into private supply chains.

Connected Entities

personMr. BucshonRepresentative who co-sponsored the bill.Map →
organizationFood and Drug AdministrationAgency whose previous work on essential medicines will inform the new list.Map →
organizationDepartment of Health and Human ServicesThe primary agency responsible for creating the list and managing the supply chaMap →
personMs. MatsuiRepresentative who introduced the bill.Map →

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy20
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record